Navigation Links
New Study Demonstrates Clinical Validity of EarlyCDT-Lung™
Date:8/5/2010

combined(1). The 5-year survival rate of approximately 16% has remained essentially unchanged over the last 40 years, due in part to the lack of early detection(2). According to the NCI, the 5-year survival rate triples to over 50% if the disease is treated when it is localized and caught at an early stage(3).

About the Study

This current publication reports on three separate cohorts, totaling 655 patients with newly-diagnosed lung cancer. All patients with lung cancer were individually matched by gender, age, and smoking history to a control individual (high-risk normal) with no previous history of cancer. Patients were from the United States, Russia, Germany, United Kingdom, and the Ukraine. Samples were run in a blinded fashion in Oncimmune's CLIA-certified laboratory in the metro Kansas City area. "The publication reports the clinical validation of EarlyCDT-Lung through training and validation datasets," said John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. "The combination of this publication and the previous technical validation publications highlight the robust development program which Oncimmune has undertaken before launching the EarlyCDT-Lung test."

"Clinical Validation of an Autoantibody Test for Lung Cancer Diagnosis" was authored by Peter Boyle, PhD, Caroline J. Chapman, PhD, Stefan Holdenrieder, M.D., Andrea Murray, PhD, Chris Robertson, PhD, '/>"/>

SOURCE Oncimmune (USA) LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
2. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Study measures single-molecule machines in action
8. Recent Study Reports Reveals that HGH May Aid Performance
9. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
10. Depth charge: Using atomic force microscopy to study subsurface structures
11. Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
(Date:8/19/2014)... VANCOUVER , Aug. 19, 2014 /PRNewswire/ - iCo ... (OTCQX: ICOTF), today reported results of its Oral ... latent HIV reservoirs.  The study, conducted by ImmuneCarta®, ... in vitro effectiveness of Oral Amp ... remain present in individuals despite intensive treatment with ...
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... August 18, 2014 According ... Market, By Application (Municipal Wastewater Treatment and Industrial ... and Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), ... by MarketsandMarkets, The market for membrane bioreactor systems ... growing at a CAGR of 15.28% between 2014 ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 2011 The 10th annual Evergreen Healthcare Foundation Gala ... and friends of the hospital together at King County,s ... million to kick off a capital campaign that will ... imaging technology.   The "Evening in Paris" ...
... At this year,s American Academy of AntiAging (A4M) conference, ... leading factors in premature aging and disease. AGEs are dangerous ... sugar that attaches to a protein or lipid without the ... completely irreversible—and cause accelerated damage to the tissues and cells. ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... it will release its unaudited financial results for the first ... 13, 2011.  The Company will host a conference call on ... 2011 at 8:00 pm China Standard Time) to review the ...
Cached Biology Technology:Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results 2
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
(Date:8/19/2014)... Science Center at San Antonio and The University of ... of more than $750,000 in grants through the San ... in 2003, SALSI is a model of how a ... center join forces for greater research and graduate education. ... focus on public health issues and diseases of global ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... Two chemicals -- trichloroethylene (TCE) and tetrachloroethylene (PCE) -- ... Base Camp Lejeune from the 1950s to 1985 have ... cancers. A new report from the National Research ... Potential Health Effects, reviews scientific evidence about the potential ...
... humans have evolved to naturally understand things like facial expressions ... found there is an ever-widening gap between what humans can ... successful adults in today,s modern society. Schools have traditionally helped ... the U.S. more may need to be done. "Schools ...
... Australian company Stadvis Pty Ltd have signed a worldwide ... predicts glycemic index (GI) and resistant starch (RS) in ... with an accurate means of testing the functional properties ... is much quicker and more cost-effective than the current ...
Cached Biology News:MU study finds connection between evolution, classroom learning 2CSIRO deal to commercialize 'artificial gut' 2
Immunochemistry 1 & 2...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
Supplemental reagent for annexin V assay....
See product name for description....
Biology Products: